世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界の子宮内膜がん治療市場 2018-2022年

Global Endometrial Cancer Therapeutics Market 2018-2022

IRTNTR23738

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年9月US$2,500
シングルユーザライセンス
110

サマリー

この調査レポートは世界の子宮内膜がん治療市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Endometrial Cancer
Endometrial cancer is a type of uterine cancer, which begins in the layer of cells that form the lining (endometrium) of the uterus of women. Unopposed endometrial estrogen exposure such as estrogen replacement therapy during menopause is associated with increased risk of developing endometrial cancer among women.
Technavio’s analysts forecast the Global Endometrial Cancer Therapeutics Market to grow at a CAGR of 5.17% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the endometrial cancer therapeutics market. To calculate the market size, the report considers the revenue generated by treatment of endometrial cancer across the globe.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, endometrial cancer therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- CELGENE
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Teva Pharmaceutical Industries
Market driver
- Increasing prevalence of endometrial cancer
- For a full, detailed list, view our report

Market challenge
- High cost associated with treatment
- For a full, detailed list, view our report

Market trend
- Immune therapy
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: PIPELINE
PART 08: MARKET SEGMENTATION BY PRODUCT
- Segmentation by product
- Comparison by product
- Chemotherapy - Market size and forecast 2017-2022
- Hormone therapy - Market size and forecast 2017-2022
- Market opportunity by product
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Immune therapy
- Personalized medicine
- Increase in small molecules in drug development pipeline
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- CELGENE
- Janssen Pharmaceuticals
- Novartis
- Pfizer
- Teva Pharmaceutical Industries
PART 16: APPENDIX
- List of abbreviations
-
-
Exhibit 01: Parent market
Exhibit 02: Global uterine cancer therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global endometrial cancer therapeutics market - Market size and forecast 2017-2022 ($ bn)
Exhibit 09: Global endometrial cancer therapeutics market - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Key clinical trials
Exhibit 20: Global endometrial cancer therapeutics market - Market share by product 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: Chemotherapy - Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Chemotherapy - Year-over-year growth 2018-2022 (%)
Exhibit 24: Hormone therapy - Market size and forecast 2017-2022 ($ bn)
Exhibit 25: Hormone therapy - Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Global endometrial cancer therapeutics market - Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: CELGENE - Overview
Exhibit 46: CELGENE - Business segments
Exhibit 47: CELGENE - Organizational developments
Exhibit 48: CELGENE - Geographic focus
Exhibit 49: CELGENE - Key offerings
Exhibit 50: CELGENE - Key customers
Exhibit 51: Janssen Pharmaceuticals - Overview
Exhibit 52: Janssen Pharmaceuticals - Business segments
Exhibit 53: Janssen Pharmaceuticals - Organizational developments
Exhibit 54: Janssen Pharmaceuticals - Geographic focus
Exhibit 55: Janssen Pharmaceuticals - Segment focus
Exhibit 56: Janssen Pharmaceuticals - Key offerings
Exhibit 57: Janssen Pharmaceuticals - Key customers
Exhibit 58: Novartis - Overview
Exhibit 59: Novartis - Business segments
Exhibit 60: Novartis - Organizational developments
Exhibit 61: Novartis - Geographic focus
Exhibit 62: Novartis - Segment focus
Exhibit 63: Novartis - Key offerings
Exhibit 64: Novartis - Key customers
Exhibit 65: Pfizer - Overview
Exhibit 66: Pfizer - Business segments
Exhibit 67: Pfizer - Organizational developments
Exhibit 68: Pfizer - Geographic focus
Exhibit 69: Pfizer - Segment focus
Exhibit 70: Pfizer - Key offerings
Exhibit 71: Pfizer - Key customers
Exhibit 72: Teva Pharmaceutical Industries - Overview
Exhibit 73: Teva Pharmaceutical Industries - Business segments
Exhibit 74: Teva Pharmaceutical Industries - Organizational developments
Exhibit 75: Teva Pharmaceutical Industries - Geographic focus
Exhibit 76: Teva Pharmaceutical Industries - Segment focus
Exhibit 77: Teva Pharmaceutical Industries - Key offerings
Exhibit 78: Teva Pharmaceutical Industries - Key customers

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る